|
On 14-mar-2024, palette life received notification of the following complaint: "on (b)(6).2024, [palette sales representative] received a phone call on her mobile phone from the patient.This patient was injected with solesta on (b)(6) 2023, by the physician.The patient complains that since the injection he has had a feeling of bowel fullness and constipation, nausea, and no appetite, he has had a ct scan that showed a mass in his rectum.He also complained of urinary urgency and frequency.An mri is scheduled for next week.The patient was advised to follow up with his physician.[palette sales representative] also reached out to [physician] via email to let him know that this patient had called with a complaint and to supply information on [patient history, current status histology, and radiographic imaging]." on 15-mar-2024 additional information was received from [palette sales representative] that stated the following: it was clarified to the [physician] that the patient reported the incident directly to the manufacturer.In addition, the patient previously reported an adverse event with his solesta injection on (b)(6) 2023 that was filed [internally within palette life complaint handling system].On (b)(6) 2024, [palette sales representative] received a phone call from solesta patient with an update on his reported adverse event.[patient] had previously sent an email with his mri results that showed what was assumed to be a solesta bleb pushing against [patient] prostate.The medical plan was to biopsy the mass by a colorectal surgeon within the same medical clinic group.[patient] reported that the biopsy did not take place because the colorectal surgeon could not palpate or identify a mass and therefore could not biopsy the tissue.[patient] plans to seek a second opinion as his urinary frequency and bladder issues continue.
|